Mark Yan

Mississauga, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 06, 2026

Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP- but not Pola-R-CHP-treated patients with DLBCL.

Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP- but not Pola-R-CHP-treated patients with DLBCL.

Journal: Blood neoplasia

Published: February 17, 2026

Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.

Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 20, 2025

Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.

Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 24, 2025

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.

Journal: Blood

Published: February 18, 2025

Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes.

Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes.

Journal: Blood advances

Published: September 03, 2024

Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials.

Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials.

Journal: Leukemia

Published: May 15, 2024

Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia.

Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia.

Journal: Leukemia & lymphoma

Published: July 14, 2022

A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia.

A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia.

Journal: Leukemia & lymphoma

Published: May 02, 2022

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

Journal: The New England journal of medicine

Published: December 14, 2021

Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome.

Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome.

Journal: Blood advances

Published: May 13, 2021

Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.

Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.

Journal: The Lancet. Oncology

Published: November 17, 2018

Showing 1-12 of 12

Last Updated: 09/26/2026